Mylan - Now a Part of Viatris
WEBMylan is now part of Viatris, a new global healthcare company committed to empowering people to live healthier at every stage of life. We encourage you to learn more about our commitment to increasing access to quality medicines for …
Mylan and Pfizer Announce Viatris as the New Company Name in …
WEBNov 12, 2019 · Formed through a combination of two highly complementary businesses, Viatris will unite Upjohn's strong leadership position in China and emerging markets with Mylan's significant presence in the U.S. and Europe, allowing the new company to have a meaningfully expanded geographic reach for Viatris' …
Mylan and Biocon Announce U.S. FDA Approval of Semglee™ …
WEBJun 11, 2020 · Mylan and Biocon Biologic's insulin glargine has received regulatory approval in more than 45 countries around the world and is the third product approved by FDA through the Mylan-Biocon Biologics collaboration.
Mylan to Acquire Meda | Mylan N.V.
WEBFeb 10, 2016 · Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company ("Mylan"), today announced a recommended public offer to the shareholders of Meda Aktiebolag (publ.) ("Meda") to tender all their shares in Meda to Mylan (the "Offer").
Mylan Announces Worldwide Collaboration with Momenta to …
WEBJan 8, 2016 · Mylan's collaboration with Momenta builds upon Mylan's existing biologics and insulin analog partnership with Biocon. The Biocon partnership includes six biosimilar programs (trastuzumab, pegfilgrastim, adalimumab, bevacizumab, etanercept and filgrastim) and three insulin analogs (glargine, lispro and aspart).
Mylan Completes Acquisition of Certain Businesses from Famy …
WEBNov 20, 2015 · The transaction brings Mylan a broad women's care portfolio, strong technical capabilities and dedicated hormone manufacturing, which, when combined with Mylan's expansive global commercial footprint and supply chain infrastructure, will create a leading women's healthcare franchise.
Mylan Laboratories Completes Matrix Laboratories Transaction
WEBJan 8, 2007 · In light of the previously- announced closing of the acquisition of 20% of Matrix's outstanding shares under an open offer to Matrix shareholders, MP Laboratories (Mauritius) Ltd, a wholly-owned subsidiary of Mylan, now owns approximately 71.5% of the voting share capital of Matrix.
Mylan Raises Offer to Acquire Perrigo | Mylan N.V.
WEBApr 8, 2015 · As a result of the Increased Offer, it is expected that, following the consummation of the transaction, Mylan shareholders will own approximately 60.7% of the outstanding Mylan ordinary shares on a fully diluted basis and former Perrigo shareholders will own approximately 39.3% of the outstanding Mylan ordinary shares on a …
Mylan Relocates Corporate Headquarters | Mylan N.V.
WEBApr 10, 2003 · Vice Chairman and CEO, Robert J. Coury stated, "Our relocation to Southpointe brings Mylan's Corporate Headquarters substantially closer to our main operating and development facility, as well as to our largest employee base.
Mylan Launches Thiamine Hydrochloride Injection
WEBMar 31, 2012 · Thiamine Hydrochloride Injection, 100 mg/mL, had U.S. sales of approximately $18.6 million for the 12 months ending March 31, 2012, according to IMS Health. Mylan is shipping this product, presented in 25-vial packs, immediately. Currently, Mylan has 169 ANDAs pending FDA approval representing $83.9 billion in annual sales, according to IMS Health.